Metoprolol Succinate/Empagliflozin/Spironolactone

琥珀酸美托洛尔/恩格列净/螺内酯

Report date: 2026/01/21 20:00:47
NME

Base Information

Drug NameMetoprolol Succinate/Empagliflozin/Spironolactone
Drug Alias NamePolypill
ClassificationSmall molecules
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitorsMineralocorticoid receptor antagonistsBeta-1 adrenergic receptor antagonists
TargetsBeta-1 adrenergic receptorSodium/glucose cotransporter 2Mineralocorticoid receptor
Therapy Area/IndicationsLipid Metabolism DisordersDiabetes Mellitus, Type 2Hypertension +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIran
CombinationsYes Metoprolol SuccinateEmpagliflozinSpironolactone
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity of Texas Southwestern Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Texas Southwestern Medical Center
Inactive CompaniesTehran University Of Medical Sciences
Active IndicationsLipid Metabolism DisordersDiabetes Mellitus, Type 2Hypertension +[6] 
Inactive IndicationsCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksN/A